Page 81 - Read Online

Page 24 of 25 Lue et al. J Cancer Metastasis Treat 2022;8:11 https://dx.doi.org/10.20517/2394-4722.2021.193

137. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse
large-B-cell lymphoma. N Engl J Med 2002;346:235-42. DOI PubMed
138. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-Cell lymphoma. J Clin Oncol
2020;38:155-65. DOI PubMed PMC
139. Gritti G, Marlton P, Phillips TJ, et al. Polatuzumab vedotin plus venetoclax with rituximab in relapsed/refractory diffuse large B-Cell
lymphoma: primary efficacy analysis of a phase IB/II study. Blood 2020;136:45-7. DOI
140. Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-
MIND): a multicentre, prospective, single-arm, phase 2 study. The Lancet Oncology 2020;21:978-88. DOI PubMed
141. Duell J, Maddocks KJ, González-barca E, et al. Subgroup analyses from L-mind, a phase II Study of tafasitamab (MOR208)
combined with lenalidomide in patients with relapsed or refractory diffuse large B-Cell lymphoma. Blood 2019;134:1582. DOI
142. Burke JM, André M, Cheson BD, et al. A phase IB, open-label, randomized study to assess safety and preliminary efficacy of
tafasitamab (MOR208) or tafasitamab + lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell
lymphoma: the first-mind trial. Blood 2019;134:2877. DOI
143. Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a
multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology 2021;22:790-800. DOI PubMed
144. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid
phagocytosis. Cell 2009;138:271-85. DOI PubMed PMC
145. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-
Hodgkin lymphoma. Cell 2010;142:699-713. DOI PubMed PMC
146. Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin’s lymphoma. N Engl J Med
2018;379:1711-21. DOI PubMed PMC
147. Schuster SJ, Bartlett NL, Assouline S, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma
patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (car-t) therapies, and is active in
treatment through multiple lines. Blood 2019;134:6. DOI
148. Olszewski AJ, Avigdor A, Babu S, et al. Single-agent mosunetuzumab is a Promising safe and efficacious chemotherapy-free
regimen for elderly/unfit patients with previously untreated diffuse large B-Cell lymphoma. Blood 2020;136:43-5. DOI
149. Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979), a Human CD20 x CD3 bispecific antibody, induces durable,
complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy.
Blood 2020;136:42-3. DOI
150. Hutchings M, Mous R, Clausen MR, et al. Subcutaneous epcoritamab induces complete responses with an encouraging safety profile
across relapsed/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior car-t therapy: updated dose
escalation data. Blood 2020;136:45-6. DOI
151. Bacac M, Colombetti S, Herter S, et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic
malignancies. Clin Cancer Res 2018;24:4785-97. DOI PubMed
152. Hutchings M, Carlo-stella C, Bachy E, et al. Glofitamab step-up dosing induces high response rates in patients with hard-to-treat
refractory or relapsed non-hodgkin lymphoma. Blood 2020;136:46-8. DOI
153. Zhang J, Zhou Z. Preclinical study of a novel tri-specific anti-CD3/CD19/CD20 T cell-engaging antibody as a potentially better
treatment for NHL. Blood 2020;136:22. DOI
154. Locke FL, Miklos DB, Jacobson CA, et al; All ZUMA-7 investigators and contributing kite members. Axicabtagene ciloleucel as
second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386:640-54. DOI PubMed
155. Kamdar M, Solomon SR, Arnason JE, et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) t
cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation
(ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from
the randomized phase 3 transform study. Blood 2021;138:91. DOI
156. Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-Cell lymphoma. N Engl J
Med 2022;386:629-39. DOI PubMed
157. Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med
2018;378:449-59. DOI PubMed PMC
158. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 2019;16:372-85. DOI PubMed PMC
159. Qin JS, Johnstone TG, Baturevych A, et al. Antitumor potency of an anti-cd19 chimeric antigen receptor T-Cell therapy,
lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib. J Immunother 2020;43:107-20. DOI PubMed PMC
160. Otáhal P, Průková D, Král V, et al. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.
Oncoimmunology 2016;5:e1115940. DOI PubMed PMC
161. Thieblemont C, Chevret S, Allain V, et al. Lenalidomide enhance CAR T-Cells Response in patients with refractory/relapsed large B
Cell lymphoma experiencing progression after infusion. Blood 2020;136:16-7. DOI
162. Rupp LJ, Schumann K, Roybal KT, et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric
antigen receptor T cells. Sci Rep 2017;7:737. DOI PubMed PMC
163. Li S, Siriwon N, Zhang X, et al. Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to
secrete checkpoint inhibitors. Clin Cancer Res 2017;23:6982-92. DOI PubMed